Clinical Trials
38 trialsSymbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
Pfizer
ATHENA
AstraZeneca
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
ModeX Therapeutics, An OPKO Health Company
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
7 Hills Pharma, LLC
DUET-HCC
Beijing Biotech
A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor
Eisai Inc.
Oral Axl/Mer/CSF1R Selective Tyrosine Kinase Inhibitor Q702 in Combination With Pembrolizumab in Patients With Selected Advanced Solid Tumors
Qurient Co., Ltd.
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
DualityBio Inc.
A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid Tumors
Takeda
SL-28 for Advanced Solid Tumours
Second Life Therapeutics
RELATIVITY-106
Bristol-Myers Squibb
ARYA-3
Eureka Therapeutics Inc.
Immune Cell Therapy for Advanced Solid Tumors
Liaoning Medical Diagnosis and Treatment Technology Research and Development Co., Ltd.
ARYA-2
Eureka Therapeutics Inc.
IT-01
Intensity Therapeutics, Inc.
MYCHELANGELO I
Omega Therapeutics
A Study to Evaluate of PM8002 Combined With PM1009 in Patients With First-line HCC
Biotheus Inc.
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Fusion Pharmaceuticals Inc.
Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene
Klus Pharma Inc.
Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC
Novartis
Phase 1/2 Study of Derazantinib (ARQ 087) in Adult Subjects With Advanced Solid Tumors With FGFR Genetic Alterations
Basilea Pharmaceutica
Safety and Efficacy of CEA-Targeted CAR-T Therapy for Relapsed/Refractory CEA+ Cancer
Chongqing Precision Biotech Co., Ltd
A Study of T3011 Administered Via Intravenously in Patients With Advanced Solid Tumors.
ImmVira Pharma Co. Ltd
Study of Irofulven in Combination With Oxaliplatin in Patients With Advanced Solid Tumors
Eisai Inc.
NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers
Nanobiotix
A Study of Emibetuzumab in Combination With Ramucirumab (LY3009806) in Participants With Advanced Cancer
Eli Lilly and Company
In-Situ Therapeutic Cancer Vaccine for Refractory Liver Cancer
Mirror Biologics, Inc.
An Individualized Anti-Cancer Vaccine Study in Patients With HCC
Mirror Biologics, Inc.
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular Carcinoma
Arbutus Biopharma Corporation
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
Leaf Vertical Inc.
Safety & Efficacy of NV1020 in Colorectal Cancer Metastatic to the Liver
MediGene
Immunotherapy of Tumor With Autologous Tumor Derived Heat Shock Protein gp96
Cure&Sure Biotech Co., LTD
Safety and Efficacy Study of DCVax-Direct in Solid Tumors
Northwest Biotherapeutics
Clinical Evaluation of the New Hypoxia Imaging Agent HX4
Siemens Molecular Imaging
Tumor Ablation With Talaporfin Sodium and Interstitial Light Emitting Diodes Treating Hepatocellular Carcinoma (HCC)
Light Sciences LLC
Study of Botanical PHY906 Plus Capecitabine for Advanced Unresectable Hepatocellular Carcinoma
PhytoCeutica
Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver
FeRx
Safety and Efficacy of Doxorubicin Adsorbed to Magnetic Beads
FeRx